Team:Nottingham/test/sponsors
The University of Nottingham is a pioneering university that provides an exceptional research-led education (TEF Gold), and an outstanding student experience. The University is home to 34,000 students in Nottingham, with an extra 11,000 students across their China and Malaysia campuses. Ranked in the UK and European top 30 and in the top 1 per cent of all universities worldwide, the University of Nottingham continues to make a huge impact across the world.
The Synthetic Biology Research Centre Nottingham (SBRC) is one of six synthetic biology research centres established by the UK Research councils BBSRC (Biotechnology and Biological Sciences Research Council) and EPSRC (Engineering and Physical Sciences Research Council). The centre concentrates on engineering bacteria to make industrially-useful products from C1-feedstocks including the greenhouse gases, carbon monoxide and carbon dioxide and methane.
The Wellcome Trust is a global charitable foundation, both politically and financially independent. The trust’s work focusses on supporting scientists and researchers, taking on big problems, fuelling imaginations, and sparking debate. They also identify priority areas where the trust can give focused, intensive support when there are real opportunities to transform lives, or drive reform to ensure that ideas reach their full potential.
The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a new organisation that brings together the UK’s seven research councils, Innovate UK and Research England to maximise the contribution of each council and create the best environment for research and innovation to flourish. Their vision is to ensure the UK maintains its world-leading position in research and innovation
Don Whitley Scientific Limited is a leading international supplier of innovative equipment and services to the microbiology and tissue culture industries. Their teams develop, manufacture, market and service instrumentation and associated products for the public and private sector - primarily for use in hospitals, public health laboratories, food testing organisations, pharmaceutical companies and research institutions. They also provide extensive contract research microbiology from our UK-based GLP-compliant laboratories.
LanzaTech is revolutionizing the way the world thinks about carbon. By turning waste carbon from a liability to an opportunity, they are accelerating the reduction of harmful emissions while creating new economic opportunities for companies, communities and countries around the world. At the heart of the LanzaTech process is their patented, wholly-owned microbes that convert carbon rich wastes and residues produced by industries such as steel manufacturing, oil refining and chemical production, as well as gases generated by gasification of forestry and agricultural residues, municipal waste into valuable fuel and chemical products through a process of gas fermentation.
The NIHR (National Institute for Health Research) Nottingham Biomedical Research Centre is improving the health of millions of people with common diseases like asthma and arthritis. They drive innovation in experimental science and translate research into breakthrough treatments, new technologies and advanced medicines. At the heart of the Nottingham BRC is their internationally renowned expertise in Magnetic Resonance Imaging (MRI). Their world-leading research focuses on hearing, gastrointestinal and liver diseases, musculoskeletal diseases, mental health and technology and respiratory diseases.
Seres Therapeutics is creating a new class of medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current approaches. Seres is a clinical biopharmaceutical company with a powerful platform to discover and develop drugs to treat diseases in multiple areas of medicine that arise from dysbiosis. Their team of drug development experts discovers and designs new medicines using their proprietary microbiome therapeutics platform.
Our sponsors
